Comparison
CJC-1295 vs Selank
Side-by-side of CJC-1295 and Selank. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
CJC-1295
CJC-1295 peptide profile: GHRH analog forms (with-DAC ~7-day half-life, no-DAC Mod GRF 1-29 ~30 min), ipamorelin pairing, recovery use, dosing, side effects.
Selank
Selank peptide benefits: tuftsin analog heptapeptide, intranasal anxiolytic and nootropic. Russian clinical data, dosing, half-life, safety.
Effects at a glance
CJC-1295
- •GHRH analog that binds the GHRH receptor on pituitary somatotrophs to release endogenous GH
- •DAC variant has ~7 day half-life via albumin binding; non-DAC variant ~30 minutes
- •Teichman 2006 trial showed sustained 2 to 10 fold IGF-1 elevation at 60 to 250 mcg/kg DAC dosing
- •Anecdotal protocols pair non-DAC CJC-1295 with Ipamorelin to mimic pulsatile GH release
- •Side effects: water retention, numbness or tingling at injection site, vivid dreams, transient flushing
- •No completed phase III RCTs; research-use-only and not FDA approved
Selank
- •Synthetic heptapeptide analog of tuftsin developed in Russia in the 1990s
- •Approved in Russia for generalized anxiety disorder and asthenic conditions
- •Russian RCTs report anxiolytic effects comparable to medazepam without sedation or dependence
- •Modulates GABAergic and serotonergic signaling and BDNF expression in preclinical models
- •Most commonly administered intranasally; subcutaneous use is anecdotal
- •No Western-validated trials; not FDA approved; research-use-only outside Russia
Side-by-side
| Attribute | CJC-1295 | Selank |
|---|---|---|
| Category | peptide | peptide |
| Also known as | CJC-1295 DAC, CJC-1295 no-DAC, Mod GRF 1-29, tesamorelin analog | TP-7, Tuftsin analog |
| Half-life (hr) ↗ | 168 | 0.5 |
| Typical dose (mg) ↗ | 0.1 | 0.4 |
| Dosing frequency | weekly (DAC); 1-3x daily (non-DAC) | 2-3x daily (intranasal) |
| Routes | subcutaneous | intranasal, subcutaneous |
| Onset (hr) | 1 | 0.25 |
| Peak (hr) | 3 | 1 |
| Molecular weight | 3367.83 | 751.85 |
| Molecular formula | C152H252N44O42 | C33H57N11O9 |
| Mechanism | Binds the GHRH receptor on pituitary somatotrophs, stimulating pulsatile growth-hormone release. The DAC modification extends plasma residence by tethering the peptide to serum albumin via a maleimide-cysteine bond. | Modulates GABAergic, serotonergic, and dopaminergic signaling. Increases BDNF expression in hippocampal neurons in preclinical models. Modulates enkephalin levels and immune cytokine signaling via tuftsin-like activity. |
| Legal status | Not FDA approved; research-use-only grey market; banned by WADA | Approved as a prescription anxiolytic in Russia; not FDA approved; research-use-only grey market in most other jurisdictions |
| WADA status | banned | unknown |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status | Not FDA approved; not scheduled; research-chemical status outside Russia |
| Pregnancy | Insufficient data; not recommended | Not recommended; insufficient data |
| CAS | 446262-90-4 | 129954-34-3 |
| PubChem CID | 91971820 | 11765600 |
| Wikidata | Q5012154 | Q4416793 |
Safety profile
CJC-1295
Common side effects
- injection-site reactions
- water retention
- numbness or tingling at injection site
- vivid dreams
- transient flushing
- head pressure or mild headache
Contraindications
- pregnancy
- active malignancy
- diabetic retinopathy (theoretical)
- history of pituitary tumor
Interactions
- Ipamorelin: synergistic GH release; commonly co-administered in anecdotal protocols(minor)
- insulin: GH-induced insulin resistance can shift glycemic control over weeks(moderate)
- corticosteroids: blunt GH-axis response; reduce expected efficacy(moderate)
Selank
Common side effects
- mild nasal irritation (intranasal)
- transient drowsiness (uncommon)
- mild headache
Contraindications
- pregnancy
- lactation
- severe psychiatric disorder (insufficient data)
Interactions
- benzodiazepines: additive anxiolytic effect; potential for over-sedation when stacked(moderate)
- SSRIs: no documented adverse interaction; co-administration described in Russian protocols(minor)
Which Should You Take?
CJC-1295 comes out ahead for most readers on the criteria we weight: 3 catalogued goals, research-only / gray-market sourcing, with a Tier-B outcome catalogued. Selank is the right call when one of the conditionals below applies.
- → If your priority is post-training recovery, pick CJC-1295.
- → If your priority is growth-hormone axis, pick CJC-1295.
- → If your priority is focus or working memory, pick Selank.
- → If your priority is anxiety reduction, pick Selank.
Edge case: Half-lives differ materially (CJC-1295 ~168 hr vs Selank ~0.5 hr). CJC-1295 reaches steady state faster; Selank is easier to dial in if tolerability is uncertain.
Default choice: CJC-1295. Wider use case, and broader goal coverage. Reach for Selank only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between CJC-1295 and Selank?
CJC-1295 and Selank differ in category (peptide vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, CJC-1295 or Selank?
CJC-1295 half-life is 168 hours; Selank half-life is 0.5 hours.
Can you stack CJC-1295 with Selank?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper